Single Dose Pharmacodynamic and Pharmacokinetic Study of DG3173

Trial Profile

Single Dose Pharmacodynamic and Pharmacokinetic Study of DG3173

Completed
Phase of Trial: Phase I

Latest Information Update: 31 May 2016

At a glance

  • Drugs Veldoreotide (Primary) ; Octreotide
  • Indications Acromegaly
  • Focus Pharmacodynamics
  • Sponsors Aspireo Pharmaceuticals
  • Most Recent Events

    • 31 May 2016 According to a Strongbridge Biopharma media release, data from this study were presented at the 18th European Congress of Endocrinology.
    • 30 Apr 2014 New trial record
    • 22 Apr 2014 Results reported in an Aspireo Pharmaceuticals media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top